Mounjaro (tirzepatide) produces more weight loss and better glycaemic control than Ozempic (semaglutide) in head-to-head trials. In SURPASS-2, Mounjaro 15mg produced 11.2kg weight loss versus 5.7kg for Ozempic 1mg over 40 weeks. Ozempic has a proven cardiovascular outcomes trial; Mounjaro's cardiovascular data reads out in 2027. If weight loss efficacy is the priority and cardiovascular history is not a concern, Mounjaro is the stronger choice. If cardiovascular protection is the priority, Ozempic has the label for it.
Ozempic and Mounjaro are not the same drug. They are not even the same type of drug, despite frequently being grouped together. Understanding why one consistently outperforms the other starts with understanding what each actually does in the body.
What they are — and why it matters
Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics one hormone, glucagon-like peptide-1, which is released naturally after eating. GLP-1 tells the brain you are full, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent way. Ozempic activates one receptor.
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is a separate gut hormone that enhances insulin secretion, appears to improve fat metabolism, and seems to work synergistically with GLP-1 to produce greater appetite suppression and weight loss than either pathway alone. Mounjaro pushes two buttons simultaneously.
This mechanistic difference is not marketing. It is the reason the efficacy gap exists. Activating both receptors produces effects that are greater than the sum of their parts, which is the leading explanation for why tirzepatide consistently outperforms semaglutide in clinical trials.
Ozempic and Wegovy are the same molecule (semaglutide) at different doses. Ozempic (up to 2mg) is approved for type 2 diabetes. Wegovy (up to 2.4mg, or 7.2mg in the new HD formulation) is approved for chronic weight management.
Mounjaro and Zepbound are the same molecule (tirzepatide) at different doses. Mounjaro (up to 15mg) is approved for type 2 diabetes. Zepbound (up to 15mg) is approved for chronic weight management.
When people ask "Ozempic vs Mounjaro" they are usually asking about semaglutide vs tirzepatide for weight loss. The brand names reflect the approved indication, not a different drug.
The head-to-head evidence
The SURPASS-2 trial (Frías et al., NEJM 2021) directly compared tirzepatide to semaglutide in 1,879 adults with type 2 diabetes over 40 weeks. It is the most rigorous head-to-head comparison available.
Results at 40 weeks: Mounjaro 5mg produced 7.6kg weight loss versus 5.7kg for Ozempic 1mg. Mounjaro 10mg produced 9.3kg. Mounjaro 15mg produced 11.2kg. Every tirzepatide dose outperformed semaglutide 1mg numerically. A1C reduction followed the same pattern: Mounjaro 15mg reduced A1C by 2.30% versus 1.86% for Ozempic 1mg.
A 2026 post-hoc analysis in Diabetes, Obesity and Metabolism confirmed that tirzepatide produced significantly greater weight loss than semaglutide at comparable treatment durations across multiple studies. Real-world data from Truveta, drawing on electronic medical records from 18% of US daily clinical care, shows the same direction of effect.
For weight management specifically, the SURMOUNT-5 trial compared Zepbound (tirzepatide 10/15mg) to Wegovy (semaglutide 2.4mg) in adults with obesity. Tirzepatide produced approximately 20-22% body weight reduction versus roughly 15% for semaglutide at maximum doses.
Where Ozempic has the advantage
Ozempic's clearest clinical advantage is cardiovascular outcomes data. The SUSTAIN-6 trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in high-risk type 2 diabetes patients. The SELECT trial extended this, showing cardiovascular benefit in adults with obesity but without diabetes. These are landmark results with a large patient population and long follow-up.
Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is expected to read out in 2027. Until that data is published, Ozempic has a proven cardiovascular label that Mounjaro does not. For patients with existing cardiovascular disease, or for whom cardiovascular protection is the primary treatment goal, Ozempic remains the better-evidenced choice by a meaningful margin.
Ozempic also has a longer safety track record by several years. The semaglutide clinical program predates tirzepatide's, and the cumulative real-world experience with millions of patients gives prescribers more familiarity with edge cases, drug interactions, and long-term effects.
Side effects — broadly similar, with differences
Both drugs share the same class of side effects: nausea, vomiting, diarrhoea, and constipation, all of which are dose-dependent and typically most pronounced during dose escalation. Both carry the class warning for thyroid C-cell tumours, based on rodent data, though this has not been confirmed in human populations at clinical doses.
The side effect profiles are more similar than different at the population level. Some studies suggest slightly higher rates of diarrhoea with tirzepatide and slightly more sustained nausea with semaglutide, but individual variation between patients is greater than the population-level differences between drugs. The most significant practical difference is that some patients who cannot tolerate semaglutide tolerate tirzepatide, and vice versa.
Both drugs are associated with lean mass loss alongside fat loss during weight reduction, typically representing 25-40% of total weight lost without active intervention. Resistance training and protein intake of at least 1.6g/kg body weight are strongly recommended with either medication to preserve muscle.
Cost and access in 2026
| Factor | Ozempic / Wegovy | Mounjaro / Zepbound |
|---|---|---|
| List price monthly | ~$900 (Ozempic) / ~$1,350 (Wegovy) | ~$1,000 (Mounjaro) / ~$1,060 (Zepbound) |
| Novo Nordisk self-pay | Wegovy ~$249-329/month (2026 programme) | Not available |
| Insurance coverage | Diabetes: usually covered. Weight loss: variable | Diabetes: usually covered. Weight loss: variable |
| Compounded availability | Limited, 503A restrictions post-shortage | Limited, similar restrictions |
| Generic timeline | Patent protection until ~2031 | Patent protection until ~2036 |
| Cardiovascular label | Yes, MACE reduction proven | Pending, SURPASS-CVOT 2027 |
| Weight loss approval | Wegovy FDA approved | Zepbound FDA approved |
| Head-to-head winner | No | Yes, SURPASS-2 and SURMOUNT-5 |
Who should choose which
What neither drug is good for
Both drugs require long-term use to maintain results. Weight typically returns when either medication is stopped, at a rate that mirrors the original loss. Neither is a short-course intervention. The decision to start is, in practice, a decision about indefinite treatment, and that context should inform the choice between them.
Neither is appropriate during pregnancy. Novo Nordisk recommends stopping Wegovy at least two months before attempting conception. Eli Lilly makes similar recommendations for Zepbound. Both have teratogenicity concerns and neither has been evaluated in pregnancy.
Neither replaces diet and exercise. The trial results that produce 15-22% weight loss are achieved alongside lifestyle intervention in controlled settings. Real-world results without those components tend to be more modest.